2019
Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma
Sethi TK, Kovach AE, Grover NS, Huang LC, Lee LA, Rubinstein SM, Wang Y, Morgan DS, Greer JP, Park SI, Thompson-Arildsen M, Yenamandra A, Vnencak-Jones CL, Reddy NM. Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma. Leukemia & Lymphoma 2019, 60: 2880-2889. PMID: 31184237, PMCID: PMC7280020, DOI: 10.1080/10428194.2019.1620942.Peer-Reviewed Original ResearchMeSH KeywordsAllelesAmino Acid SubstitutionBiomarkers, TumorCentral Nervous System NeoplasmsCombined Modality TherapyGenetic Association StudiesGenetic Predisposition to DiseaseHumansImmunohistochemistryIn Situ Hybridization, FluorescenceLymphocytes, Tumor-InfiltratingMacrophagesMutationMyeloid Differentiation Factor 88Neoplasm StagingPrognosisProgrammed Cell Death 1 ReceptorSignal TransductionSurvival AnalysisT-LymphocytesConceptsPD-1PD-L1Positive tumorsClinicopathologic correlatesT cellsPrimary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphomaPD-L1 positive tumorsEpstein-Barr virus infectionCentral nervous system lymphomaPotential targetable pathwayPD-L1 expressionProtein expressionNervous system lymphomaMyD88 protein expressionMYD88 L265P mutationSystemic lymphomaSystem lymphomaLymphoma patientsMacrophage infiltrationPoor prognosisVirus infectionTargetable pathwaysL265P mutationPathway alterations
2018
Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies
Sethi TK, Reddy NM. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leukemia & Lymphoma 2018, 60: 6-18. PMID: 29741421, DOI: 10.1080/10428194.2018.1466296.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAge FactorsAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsyBone MarrowBrainCentral Nervous System NeoplasmsChemoradiotherapyCognitive DysfunctionCranial IrradiationFemaleHumansLymphoma, Large B-Cell, DiffuseMagnetic Resonance ImagingMiddle AgedNeoplasm Recurrence, LocalPrognosisProgression-Free SurvivalRemission InductionStem Cell TransplantationTransplantation, AutologousConceptsPrimary central nervous lymphomaDiffuse large B-cell lymphoma histologyPrimary central nervous system lymphomaAutologous stem cell transplantCentral nervous system lymphomaMulti-agent chemotherapyNervous system lymphomaStem cell transplantNon-Hodgkin lymphomaLong-term toxicityEligible patientsImmunotherapy optionsRelapsed diseaseAggressive presentationUpfront therapySystem lymphomaCell transplantFrontline treatmentPathogenetic pathwaysLymphoma histologyCurrent evidenceFrontline strategyLymphomaTherapyOngoing studies